Abstract: In various aspects of the present invention, nanoparticle compositions are provided which comprise (a) nanoparticles comprising at least one biodegradable polymer and (b) at least one pharmaceutical associated with the nanoparticles. In other aspects of the present invention, methods of forming nanoparticles compositions are provided, which comprise contacting a first liquid that comprises one or more biodegradable polymers dissolved in a first solvent with a second liquid that comprises a second solvent which is miscible with the first solvent while being a non-solvent for the one or more biodegradable polymers, such that nanoparticles are formed.

Abstract: The subject of this application is the use of film-forming polyurethanes that are used in hair care agents or mixtures of these polyurethanes with other polymers in pharmaceutical preparations for dermal or transdermal administration of active ingredients, as well as patches and pharmaceutical preparations that contain these hair care polyurethanes.

Abstract: The subject of the present invention is solid dosage form containing cytisine and ancillary substances characterised in that it contains from 0.1% to 5% micronised cytisine, wherein all molecules have a diameter less than from 10 ???, corn starch from 40% to 60%, preferably 99.9% particles sized from 5 ??? to 25 ???, macrocrystalline cellulose in an amount from 40% to 60%, preferably the particle size is: 99% below 38 ???, wherein the mass ratio of ancillary substances to the active ingredient is from 1:19 to 1:999 and is in the form of a hard capsule as well as a method of obtaining it.

Abstract: A method of encapsulating a volatile, water-soluble substance in capsules having a hydrogel shell and an oily interior includes (i) providing blank capsules having a hydrogel shell and an oily interior and (ii) immersing the capsules in an aqueous solution of the volatile, water-soluble substance for a time sufficient for them to load to a desired extent with the volatile, water-soluble substance. The aqueous solution additionally has dissolved therein to saturation point at least one water-soluble, non-volatile material. The method permits the easy and durable encapsulation of volatile materials that hitherto have been difficult to encapsulate.

Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.

Abstract: Described are personal care compositions comprising a polymer comprising: (a) one or more polymer comprising, as polymerized units, (i) 75% to 35% by weight, based on the weight of said polymer, one or more (meth)acrylate monomer selected from at least one of C1-C4 (meth)acrylate, (meth)acrylic acid, styrene, or substituted styrene, and (ii) 25% to 65% by weight, based on the weight of said polymer, one or more hydrophobic monomer, including hydrophobically substituted (meth)acrylate monomers, with alkyl chain length from C8 to C22 and, (iii) optionally crosslinker, and, (b) at least one personal care active. Optionally, the polymer further includes a stage 2 polymer comprising, as polymerized units, (i) 10-99% of one or more monomer which has a Tg of more than 80° C. after polymer formation, (ii) 1-10% of one or more (meth)acrylate monomer containing acid functional group, and (iii) optionally, a crosslinker.

Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.

Abstract: The present invention provides novel use of the polymeric films comprising halloysite nanotubes as a packaging material for food products. Said halloysite nanotubes are incorporated with active agents such as antibacterial agents preferably of natural type for providing antibacterial, barrier and ethylene scavenging properties.

Abstract: A film for the retention and controlled release of organic or inorganic molecules consists essentially of a phyllosilicate clay and a organic polyanion. The film may be a built-up layered film of alternating layers of the clay and the polyanion. Organic or inorganic molecules are absorbed into the film from solution, and released in response to changes in the film's environment. The film may be built up using layer-by-layer (LbL) methods, or deposited on a substrate from a mixture of the clay and polyanion. Articles may be coated with the film by the same methods. The film is useful for the controlled release of antibiotics in response to infections, and also retains antibiotics such that bacteria may be killed by direct contact with the film.

Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.

Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Abstract: Acidic aqueous compositions for elimination of spores of spore forming bacteria comprise from about 100 to about 2000 ppm dissolved chlorine dioxide and a surfactant system having both a wetting effect and a spore solubilising effect.

Abstract: Oral delivery systems including at least one encapsulated active are provided. The oral delivery systems include at least one active component; and a polymer matrix at least partially encapsulating the at least one active component. In some embodiments, the polymer matrix has a tensile strength of at least about 6,500 psi and/or includes at least one polymer having a water absorption of about 0.01% to about 50% by weight. The at least one active component may be an oral care active, which may be encapsulated alone or in combination with other actives, such as a taste masking active.

Abstract: There is provided a non-water soluble drug delivery composition comprising a conjugate and a polymer matrix wherein exposure of the composition to electromagnetic radiation at a suitable pre-determined wavelength and intensity induces release of the active ingredient from the composition. The conjugate is attached to the polymer matrix through non-covalent interactions. There is also provided a drug delivery apparatus formed from the drug delivery composition.

Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with 3,3-dimethyl-1-butanol (DMB) and related compounds, and pharmaceutical formulations thereof. In other embodiments, the present invention provides methods of administering a gut flora targeting antibiotic to a subject prior to a procedure that is associated with a risk of causing thrombosis, heart-attack, and/or platelet hyper-responsiveness.

Abstract: Methods and cosmetic compositions for conditioning the skin, utilizing as active ingredients selected compounds structurally related to astragenols, cycloastragenols, and/or protopanaxatriols, are provided. Such compounds include those of formulas (I), (II) and (III) described herein.

Abstract: Disclosed is a method for producing resin particles, which can impart a desired function to the surface of resin particles efficiently and simply. Also disclosed are resin particles produced by the method. The method produces resin particles by melting and mixing an acidic-group-containing thermoplastic resin or elastomer with filler particles and a water-soluble material to give a resin composition containing resin fine particles formed by the thermoplastic resin and the filler particles and dispersed in a matrix including the water-soluble material; and removing the matrix component from the resin composition, to give the resin particles. The resulting resin particles each include a core particle including the acidic-group-containing thermoplastic resin or elastomer, and the filler particles immobilized on the outside of the core particle. The acidic group is preferably carboxyl group or carboxylic anhydride group.

Abstract: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on fosetyl-Al, propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance.

Abstract: The invention provides a process for producing a composition comprising natural alumino-silicate minerals having improved reactivity for use in methods of animal husbandry, veterinary and pharmaceutical treatment, comprising irradiating natural alumino-silicate minerals in a liquid suspension with transverse electromagnetic wave radiation in the range of 1,800 MHz to 3,000 MHz, the liquid suspension having a boiling temperature of below 120° C. The invention also provides a method of treating digestive ailments in animals comprising administering to an animal in need of same an effective amount of a composition comprising at least one natural alumina-silicate mineral which has been irradiated with transverse electromagnetic wave radiation in the range of 1,800 MHz to 3,000 MHz.

Abstract: This document discloses molecules having the following formula (Formula One) and processes related thereto.